ISSN 2063-5346

COVID-19 REINFECTION: A COMPREHENSIVE REVIEW OF THE CURRENT EVIDENCE AND IMPLICATIONS FOR PUBLIC HEALTH MEASURES

Mukesh Kumar Gupta[1], Sai Prakash Panigrahi[2], Maheswar Prasad Deep[3], Jayita Roy[4], Jharana Palei[5], Surajit Barman[6], Sandeep Kumar Sonkar[7], Vijay Kumar Patel[8*]

Article History: Received: 10.05.2023 Revised: 29.05.2023 Accepted: 09.06.2023

Abstract

The global pandemic has resulted in unprecedented challenges for public health systems worldwide since the emergence of the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019. A growing body of evidence has revealed that people who have recovered from COVID-19 may still be at risk of contracting SARS-CoV-2 again, raising questions about long-term immunity and the efficacy of vaccination campaigns. In this comprehensive review, we provide a comprehensive overview of the current evidence on COVID-19 reinfection, including the clinical characteristics, risk factors, immune response, and implications for public health measures, with a focus on recent research findings and relevant references.

[1]Associate Professor, Department of Pharmacy, Radha Govind University, Ramgarh, Jharkhand, India.

[2]Assistant Professor, Department of Pharmacy, Radha Govind University, Ramgarh, Jharkhand, India.

[3]Assistant professor, Department of Pharmacy, Radha Govind University, Ramgarh, Jharkhand, India.

[4]Assistant professor, Department of Pharmacy, Radha Govind University, Ramgarh, Jharkhand, India.

[5]Assistant professor, Department of Pharmacy, Radha Govind University, Ramgarh, Jharkhand, India.

[6]Assistant professor, Department of Pharmacy, Radha Govind University, Ramgarh, Jharkhand, India.

[7]Associate Professor, Rungta College of Pharmaceutical Sciences and Research, Raipur, Chhattisgarh, India.

[8]Associate Professor, Pushpedra College of Pharmacy, Ambikapur, Chhattisgarh, India.

*Corresponding Author : Vijay Kumar Patel Associate Professor, Pushpedra College of Pharmacy, Ambikapur, Chhattisgarh, India.

Email ID: vijay0305@gmail.com,

DOI:10.48047/ecb/2023.12.9.101

Introduction

COVID-19, caused by SARS-CoV-2, was first identified in December 2019 in Wuhan, China, and has since spread globally, leading to a pandemic that has posed immense challenges to public health systems and economies worldwide (Organization World Health 2020, Wu and McGoogan 2020). As the pandemic has progressed, there have been reports of individuals who have recovered from COVID-19 testing positive for SARS-CoV-2 again, indicating the possibility of reinfection. This phenomenon has raised concerns about the durability of immunity against SARS-CoV-2, the potential for recurrent outbreaks, and the effectiveness of vaccination programs (Zheng 2020, Su et al. 2016). In this review, we aim to provide a comprehensive overview of the current evidence on COVID-19 reinfection, including the clinical characteristics, risk factors, immune response, and implications for public health measures. We will focus on recent research findings and relevant references to provide an up-to-date analysis of this rapidly evolving field.

2. Clinical Characteristics of COVID-19 Reinfection

COVID-19 reinfection refers to the occurrence of a subsequent episode of symptomatic COVID-19 after the resolution of a previous infection. Studies have reported varying clinical characteristics of COVID-19 reinfection, with some cases being milder and others being more severe compared to the primary infection (Centers for Disease Control and Prevention 2021). The term "reinfection" with the coronavirus refers to a situation in which a patient has already been exposed to the virus, recovered, and then contracted it once more as a result of the virus reactivating in the patient's body or being attacked by a mutant virus with a different genetic makeup (Patel, et al. 2022). Epidemiological, clinical, serological, and genomic examinations of the ongoing virus shedding from the first infection provided evidence of the reinfection (To et al. 2020). COVID-19 reinfection have been reported in a number of different parts of the world, including Hong Kong, South Korea, China, Taiwan, Japan, Russia, the United States of America, Qatar, Belgium, Ecuador, Brazil, Mexico, Israel, Canada, Switzerland, Sweden, Colombia, Germany, and European nations. The symptoms of COVID-19 reinfection are generally similar to those of the primary infection and may include fever, cough, shortness of breath, fatigue, loss of taste or smell, and respiratory distress. In a study conducted in Hong Kong, 142 individuals with COVID-19 reinfection were compared to a matched group of 1,002 individuals with primary COVID-19 infection (To et al. 2020). The study found that the symptoms of COVID-19 reinfection were generally milder than those of the primary infection, with fewer cases

of fever, cough, and shortness of breath. However, some cases of reinfection were associated with more severe respiratory symptoms and required hospitalization. Another study conducted in the United States found that the clinical characteristics of COVID-19 reinfection were similar to those of the primary infection, with most cases being mild or asymptomatic (Tillett et al. 2021). However, the study also identified a small proportion of reinfection cases that were associated with more severe disease requiring hospitalization, especially in older adults and individuals with comorbidities.

3. Risk Factors for COVID-19 Reinfection

There are a number of risk factors for COVID-19 reinfection. Age, sex, comorbidities, and the presence of antibodies against SARS-CoV-2 are a few of these. Age has consistently been identified as a risk factor for COVID-19 reinfection, with studies demonstrating that people 65 years of age and older are more at risk than younger people. Another risk factor that has been mentioned is gender, with some studies suggesting that men may

be more susceptible to reinfection than women (World Health Organisation, 2021). The risk of COVID-19 reinfection has also been linked to comorbid conditions like diabetes, obesity, cardiovascular disease, and respiratory illness. People who have underlying medical issues may have immune systems that are weak, which could make them more vulnerable to reinfection. Furthermore, those who have previously tested positive for SARS-CoV-2 and recovered might still have some immunity, but over time, this immunity may wane, leaving them open to reinfection. It has been hypothesised that immunity against reinfection is conferred by antibodies against SARS-CoV-2, acquired either through prior infection or vaccination. Recent research, however, has revealed that immunity against reinfection is not always ensured by the presence of antibodies (Li et al. 2020). Some people may have lower antibody levels than others, which could increase their risk of reinfection. Moreover, emerging variants of SARS-CoV-2 may have the potential to evade the immune response, further increasing the risk of reinfection (Van Elslande et al. 2020, Long et al. 2020).

4. Immune Response to SARS-CoV-2 and Implications for Reinfection

The risk of reinfection is significantly influenced by the immune response to SARS-CoV-2. The immune system responds to a primary infection by producing antibodies and activating T cells, which are essential elements of the immune response against viral infections (Oliveira et al. 2020). Studies have shown that COVID-19 survivors typically produce antibodies against SARS-CoV-2, though the quantity and persistence of these antibodies can vary. Reinfections have been documented even in

people with detectable antibodies, and recent research suggests that the antibody response may wane over time (Kumar et al. 2020, Sciscent et al. 2021). This suggests that the presence of antibodies alone may not provide long-term immunity against SARS-CoV-2. T cells, another component of the immune response, also play a role in protecting against reinfection. T cells assist in identifying and eliminating infected cells, thereby limiting the virus' ability to spread. Studies have revealed that COVID-19 survivors typically develop T cell defences against SARS-CoV-2 (Oliveira et al. 2020). T cell immunity against reinfection is still being researched, however, and more studies are required to fully comprehend its duration and effectiveness (Shirbhate et al. 2020). The immune response to COVID-19 reinfection has been made more difficult by the emergence of SARS-CoV-2 variants. Variants have been linked to increased transmissibility and the potential to evade the immune response, including antibodies produced from prior infections or vaccination, like the B.1.1.7 variant (first identified in the UK), the B.1.351 variant (first identified in South Africa), and the P.1 variant (first identified in Brazil). These variants may pose a higher risk of reinfection and may have implications for public health measures, such as vaccination strategies and the need for booster doses (Chen et al. 2020, Wang et al. 2020).

5. Diagnostic Challenges and Confirmation of COVID-19 Reinfection

Confirming COVID-19 reinfection can be difficult due to a number of variables, including diagnostic testing limitations and the likelihood of protracted viral shedding. In order to diagnose SARS-CoV-2 infection, diagnostic procedures including reverse transcription-polymerase chain reaction (RT-PCR) assays are frequently performed, however they may not always be able to distinguish between a new infection and viral shedding from a prior illness. Additionally, elements including the date of sample collection, the calibre of the sample, and the presence of SARS-CoV-2 mutations might influence how accurate RT-PCR assays are (Hansen et al. 2021) . Researchers frequently combine clinical symptoms, epidemiological data, and

laboratory findings to prove reinfection. These methods include RT-PCR testing, whole-genome sequencing of virus isolates, and serological testing to look for antibodies against SARS-CoV-2. The genetic differences between viral isolates from the initial and subsequent infections can be identified with whole-genome sequencing, which is crucial evidence for reinfection. The presence of antibodies against SARS-CoV-2 can be detected through serological testing and may be a sign of previous infection and potential immunity. However, there may be drawbacks to serological testing as well, such as variations in antibody levels between individuals

and the potential for false-positive or false-negative results. Clinical symptoms and epidemiological data, such as a history of a prior COVID-19 infection, followed by a period of recovery and the onset of new symptoms consistent with COVID-19, may in some circumstances lead to the suspicion of reinfection. However, confirmation of reinfection may require further testing, including laboratory analysis and sequencing of viral isolates, to definitively establish the presence of a new infection (Sheehan et al. 2021).

6. COVID-19 Waves and Reinfections

COVID-19 waves are the cycles of infections that take place during a pandemic, where the number of cases first increases and then eventually decreases. Many nations, including Kyrgyzstan, Australia, South Korea, Israel, New Zealand, India, Japan, Spain, the United States of America, and the United Kingdom, can see these waves (Patel et al. 2022). The UK virus, the South African virus, the B.1.617 variant, and the double mutant form of SARS-CoV-2 have all emerged as new coronavirus strains, though the precise cause of these waves is still unknown. These variations can avoid the human immune system while being extremely contagious. Reinfection with COVID-19 happens when patients who have already recovered from the illness contract it once more. The likelihood of COVID- 19 reinfection during various waves was recently clarified by a Danish study (Toro-Huamanchumo et al. 2022). According to the study, the risk of reinfection during the first wave, which occurred between March and May 2020, was 0.65% (a second PCR test revealed positive results for 72 out of 11,068 people). However, the rate of reinfection increased noticeably to 3.3% during the second wave, which took place from September to December 2020 (16,819 out of 514,271 people tested positive in a PCR test again). This suggests that, compared to earlier COVID-19 infections, the rate of reinfection was five times higher during the second wave (Hansen et al., 2021).

7. Herd Immunity and COVID-19 Reinfection

Herd immunity is a term used in public health to describe a situation in which a large enough percentage of the population has acquired immunity to a specific virus, thereby defending the entire community from further outbreaks. This immunity can be acquired through vaccination or by people who have already contracted the infection and have developed defences against subsequent infections. It is crucial to remember that the idea of herd immunity mainly refers to a particular virus strain. When it comes to fresh or mutant strains of the original virus, herd immunity's effectiveness is constrained. The immune system may be able to evade or be bypassed by these variants, making

earlier immunity less effective. Herd immunity might not provide enough defence against various virus variants given the prevalence of new virus variants. To combat the problems posed by these new variants, it is essential to modify public health policies and vaccination programmes (Ren et al. 2022). In order to lessen the effects of COVID-19 and prevent reinfections, monitoring and understanding the characteristics of emerging variants, in

addition to ongoing vaccination efforts, remain crucial (Patel et al. 2022).

8. Implications for Public Health Measures and Future Research

The phenomenon of COVID-19 reinfection has significant effects on public health initiatives, such as vaccination plans, infection prevention strategies, and regulations pertaining to those who have recovered from COVID-19 (Le Page 2022). The prevention of COVID-19 has been aided by vaccination, which has been promoted in numerous nations worldwide. The emergence of reinfections, however, raises concerns about the durability of vaccine protection and the requirement for booster shots. According to studies, vaccination can significantly lower the risk of developing a serious illness and needing hospitalisation as a result of COVID-19, and it is still advised for people who have recovered from the virus. Immune responses, such as antibody and T cell responses, may be boosted by vaccination and may offer more defence against reinfection (Shirbhate et al. 2021). Research is still being done on the longevity of immunity brought on by vaccination, as well as the potential for vaccine protection against new SARS-CoV-2 variants. Other public health measures, such as using masks, washing your hands properly, and keeping a physical distance continue to be crucial in limiting the spread of SARS-CoV-2 and the possibility of reinfection. These measures are in addition to vaccination. These precautions are especially crucial for people who have recovered from COVID-19 because reinfection is still a possibility even after the initial infection has been treated. To fully comprehend the phenomenon of COVID-19 reinfection, including the risk factors, immune response, and implications for public health measures, more research is required. To ascertain the duration of immunity following recovery from COVID-19 and vaccination, the efficacy of vaccines against newly emerging SARS-CoV-2 variants, and the potential need for booster doses, long-term studies are required. The mechanisms by which SARS-CoV-2 variants evade the immune system as well as methods to strengthen the immune response against reinfection are still being studied (Patel et al. 2021)

9. Conclusion

The complicated phenomenon of COVID-19 reinfection complicates our understanding of the immune response to SARS-CoV-2 and has significant ramifications for public health policies. Even though reinfections are relatively uncommon, they have been reported in a number of populations and can happen in people who have antibodies to SARS-CoV-2 that can be detected. The likelihood of reinfection may be influenced by elements like the timing and length of immunity, the existence of SARS-CoV-2 variants, and individual risk factors. Due to diagnostic limitations, it can be difficult to confirm reinfection; for complete confirmation, a combination of clinical symptoms, epidemiological data, and laboratory testing may be required. Current research indicates that vaccination can lower the risk of developing severe illness and needing to be hospitalised, and vaccination is still an essential weapon in the fight against COVID-19. However, the possibility of reinfection calls into question the durability of vaccines and the necessity of booster shots. To comprehend the immune response to SARS-CoV-2, the risk factors for reinfection, and the efficacy of vaccines against emerging variants, more research is required. The ongoing tracking and investigation of COVID-19 reinfection will be crucial for informing public health policies and tactics to contain the pandemic.

References

1. Centers for Disease Control and Prevention (CDC). 2021. COVID-19 reinfection. Available at: https://www.cdc.gov/coronavirus/2019

-ncov/your-health/reinfection.html

2. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J.A., Yu, T., Zhang, X. and Zhang, L., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395(10223), 507-513. doi:10.1016/S0140-6736(20)30211-7.
3. Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E.J.M., Simmons, R., Campbell, S., 2021. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health- care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet. 397(10283), 1459-1469. doi:10.1016/S0140-6736(21)00675-9.
4. Hansen, C. H., Michlmayr, D., Gubbels, S. M. T., Molback K., 2021. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet, 397(10280), 1204-1212.
5. Hansen, C. H., Michlmayr, D., Gubbels, S.M., Mølbak, K., Ethelberg, S., 2021. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The Lancet. 397(10280), 1204- 1212. doi:10.1016/S0140-6736(21)00575-4.
6. Kumar, S., Nyodu, R., Maurya, V.K., Saxena, S.K., 2020. Host immune response and immunobiology of human sars-cov-2 infection. Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics, Available at SSRN: https://ssrn.com/abstract=3688220 or http://dx.doi.org/10.2139/ssrn.3688220 43-53. doi:10.1007/978-981-15-4814-7_5.
7. Le Page M., 2022. The risks from covid-19 reinfection. New Sci. 2022 Jul 9;255(3394):21. doi: 10.1016/S0262-4079(22)01208-8.
8. Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang,

Q. and Wu, J. (2020) 'Coronavirus infections and immune responses', Journal of Medical Virology 92(4), 424-432. https://doi.org/10.1002/jmv.25685.

9. Long, Q.X., Tang, X.J., Shi, Q.L., Li, Q., Deng, H.J., Yuan, J., Hu, J.L., Xu, W., Zhang, Y., Lv, F.J., Su, K., Zhang, F., Gong, J., Wu, B., Liu, X.M., Li, J.J., Qiu, J.F., Chen, J., Huang, A.L., 2020. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine 26(8), 1200-1204. doi: 10.1038/s41591-020-0965-6. doi:10.1038/s41591-020-0965-6.
10. Oliveira, D. S., Medeiros, N. I., Gomes, J.A.S., 2020. Immune response in COVID-19: What do we currently know? Microbial pathogenesis 148, 104484-104484. doi:10.1016/j.micpath.2020.104484.
11. Paraskevis, D., Kostaki, E.G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., Tsiodras, S., 2020. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection, Genetics and Evolution 79, 104212. https://doi.org/10.1016/j.meegid.2020.104212.
12. Patel, V.K., Shirbhate, E., Patel, P., Veerasamy, R., Sharma, P.C., Rajak, H., 2021. Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. Beni Suef Univ

J Basic Appl Sci. 10(1):78. doi: 10.1186/s43088-021-00165-0.

13. Patel, V.K., Shirbhate, E., Rajak, H., 2022. Chapter Two - Coronavirus reinfections: An outlook on evidences and effects. In Lessons from COVID-19. A. Kaklauskas, A. Abraham,

K. Okoye, and S. Guggari, eds. Pp. 19-40: Academic Press.

14. Ren, X., Zhou, J., Guo J., Hao, C., Zheng, M., Zhang, R., Huang, Q., Yao, X., Li, R., Jin, Y., 2022. Reinfection in patients with COVID-19: a systematic review. Glob Health Res Policy. 29;7(1):12.

15. Sciscent, B.Y., Eisele, C.D., Ho, L., King, S.D., Jain, R., Golamari, R.R., 2021. COVID-19 reinfection: the role of natural immunity, vaccines, and variants. J Community Hosp Intern Med Perspect. 15;11(6):733-739.

16. Shastri, J., Parikh, S., Agarwal, S., Chatterjee, N., Pathak, M., Sharma, C., Kanakan, A., Srinivasa Vasudevan, J., Maurya, R., Fatihi, S., 2020. Whole genome sequencing confirmed SARS-CoV-2 reinfections among healthcare workers in India with increased severity in the second episode. The Lancet https://ssrn.com/abstract=3688220 or http://dx.doi.org/10.2139/ssrn.3688220 43-53. doi:10.1007/978-981-15-4814-7_5.

17. Sheehan, M. M., Reddy, A. J., Rothberg, M. B., 2021. Reinfection rates among patients who previously tested positive for COVID-19: a systematic review and meta-analysis. Clinical Infectious Diseases, doi: 10.1097/CM9.0000000000001892.

18. Shirbhate E., Patel P., Patel V.K., Veerasamy R., Sharma, P.C., Sinha B.N., Rajak H. Synthetic and semi-synthetic drugs as a promising therapeutic option for the treatment of COVID-19. Mini Rev Med Chem. 2021;21(8):1004-1016.

19. Shirbhate, E., Patel, P., Patel, V.K., Veerasamy, R., Sharma, P.C., Sinha, B.N., Rajak, H., 2020. Synthetic and semi-synthetic drugs as promising therapeutic option for the treatment of COVID-19. Mini Rev Med Chem. 21(8), 1004-1016. , doi:10.2174/1389557520666201204162103.

20. Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., Liu, W., Bi, Y., Gao, G.F., 2016. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol 24(6), 490-502. doi:10.1016/j.tim.2016.03.003.

21. Tillett, R.L., Sevinsky, J.R., Hartley, P.D., Kerwin, H., Crawford, N., Gorzalski, A., Laverdure, C., Verma, S. C., Rossetto, C.C., Jackson, D., Farrell, M.J., Van Hooser, S. and

Pandori, M., 2021. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 21(1), 52-58. doi:10.1016/s1473-3099(20)30764-7.

22. To, K. K.W., Hung, I. F.N., Ip, J. D., Chu, A. W.H., Chan, W.M., Tam, A. R., Fong, C. H.Y., Yuan, S., Tsoi, H.W., Ng, A. C.K., Lee, L. L.Y., Wan, P., Tso, E., To, W.K., Tsang, D., Chan, K.H., Huang, J.D., Kok, K.-H., Cheng, V.C.C., Yuen, K.Y., 2020. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical Infectious Diseases. doi:10.1093/cid/ciaa1275.

23. Toro-Huamanchumo C.J., Hilario-Gomez M.M., Pinedo-Castillo L., Zumarán-Nuñez C.J., Espinoza-Gonzales F., Caballero-Alvarado J., Rodriguez-Morales AJ, Barboza JJ. Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review. doi: 10.1016/j.nmni.2022.101021.

24. Van Elslande, J., Vermeersch, P.,

Vandervoort, K., Wawina-Bokalanga, T., Vanmechelen, B., Wollants, E., Laenen, L., André, E., Van Ranst, M., Lagrou, K. and Maes, P. 2020. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. doi: 10.1093/cid/ciaa1330.

25. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in wuhan, china. JAMA 323(11), 1061-1069. doi: 10.1001/jama.2020.1585.
26. Wu, Z., McGoogan, J. M., 2020. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 323(13), 1239-1242. doi:10.1001/jama.2020.2648.
27. Zheng, J., 2020. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. International journal of biological sciences 16(10), 1678-1685. doi:10.7150/ijbs.45053.